LenoMed Medical Secures RMB 50 Million Series B Funding to Advance Closed-Loop Glucose Control System

VCBeat (WeChat ID: vcbeat) has learned that on December 10, LenoMed Medical (Shanghai) Co., Ltd. (“LenoMed”), a medical device company specializing in chronic disease management, announced the completion of its RMB 50 million Series B financing round, invested by F-Prime Capital. The proceeds from this round will be used to expand research and development of products for the treatment, monitoring, and management of chronic diseases, including diabetes, thereby strengthening the company’s product portfolio in the fields of diabetes and endocrinology.

Kailian Medical’s current core products under development and production include precision drug infusion systems such as the InnoTech insulin pump and the InnoPump pituitary hormone pump. In the field of diabetes care, the company is exploring the development of closed-loop glucose control systems by integrating continuous glucose monitoring (CGM) technology with insulin pumps, thereby assisting patients in disease management.

In the field of endocrinology, particularly for disorders caused by dysfunction of the hypothalamic-pituitary-gonadal axis, a new generation of micro-dosing device, InnoPump, has been innovatively developed. Kailian Medical obtained ISO 13485 certification in 2017, and its core product, the InnoTech insulin pump, has received CE approval. Currently, both the InnoTech insulin pump and the InnoPump pituitary hormone pump have entered the registration process and are expected to be launched in the Chinese market in the second half of 2019, benefiting patients with endocrine disorders such as diabetes and gonadal dysgenesis in China.

Kailian Medical adheres to a product design philosophy centered on providing affordable and user-friendly solutions. Its independently developed and manufactured drug infusion systems significantly reduce the cost of treating diabetes and endocrine disorders, while ensuring advanced technological standards, strict quality control, and continuous improvement in patient prognostic outcomes. By incorporating human-centered design and intelligent operation, Kailian Medical simplifies the user experience for patients. All devices are equipped with Bluetooth Low Energy (BLE) technology, connecting to patients’ mobile devices to transmit real-time data generated during disease treatment and management. A professional cloud-based backend system has been established around disease management, leveraging algorithms to analyze large volumes of data and deliver more precise treatment plans. Meanwhile, attending physicians can promptly access shared data to make clear and informed adjustments to treatment strategies.

Xiaomin Huang, Founder and CEO of Kailian Medical, stated, “We are delighted to have top-tier investment firms such as Shoudao Capital invest in Kailian Medical. This support will enable us to further deepen our expertise in the field of drug infusion for chronic diseases, including diabetes, and solidify our leading position in the industry. This financing will also help us continuously explore innovative business models and leverage our independently developed and manufactured devices to improve the efficiency of pump therapy for patients with chronic conditions such as diabetes, thereby enhancing their quality of life.”

Steady Capital is the proprietary investment arm of Fidelity International. With over 20 years of investment experience in China’s healthcare sector, it focuses on early-stage medical investments and has built a strategic layout across the entire industry chain. Diabetes is one of the key disease areas prioritized by Steady Capital.

Lin Rui, Partner at STOA Capital China, stated: “The Kailian team is the first in China to independently develop and manufacture insulin pumps. They possess extensive experience in the field of drug infusion and demonstrate strong capabilities in original technological innovation. Product quality and stability are critical to treatment safety, resulting in high barriers to entry. We are optimistic that their intelligent solutions will enhance the efficiency of current chronic disease management and reduce overall treatment costs. Medical devices are one of our key focus areas, and we have established platform-based layouts across multiple important sub-sectors.”

"In the critical field of diabetes, Stord Capital has established a leading presence in pharmaceuticals and stem cell therapy through Hua Medicine (02552.HK) and Semma Therapeutics. Our investment in Kailian Medical further completes our value chain layout in medical devices and patient management. We are pleased to support their continued growth."

As one of the most prevalent chronic diseases, diabetes continues to see a rising number of patients worldwide. According to the 8th edition of the Diabetes Atlas, recently released by the International Diabetes Federation (IDF), there were approximately 425 million adults aged 20–79 living with diabetes globally in 2017, a figure projected to reach 629 million by 2045. China has the largest diabetic population in the world, with 114 million adult patients in 2017, expected to rise to around 150 million by 2045. The vast patient base, the long-term medication requirements characteristic of chronic disease management, and users’ increasingly strong awareness and habits regarding blood glucose control have propelled the diabetes management market into a massive industry valued at hundreds of billions of yuan. Against this backdrop, Kailian Medical and its team are committed to providing doctors and patients with the most professional lifecycle management solutions for chronic diseases through technological research and development and product manufacturing.

Kailian Medical, established in 2014, is an innovative medical technology enterprise primarily focused on the research and development, manufacturing, and sales of high-end medical devices. Leveraging its proprietary micro-infusion and control technology platforms, and integrating biosensors with internet-based healthcare technologies, Kailian Medical develops closed-loop systems tailored to the needs of patients with chronic diseases. The company is committed to providing comprehensive solutions for patients suffering from chronic conditions such as diabetes and endocrine disorders. With over 15 years of expertise in micro-infusion technology R&D, Kailian Medical innovatively develops and manufactures the InnoTech insulin pump, drug infusion pumps, and related consumables.

Currently, Kailian Medical’s R&D pipeline covers: high-, mid-, and low-end products for diabetes management, such as electronic insulin pens, insulin pumps, patch pumps, and related consumables; drug infusion devices for conditions including pituitary dysfunction and neurological disorders; and disease management systems and supporting hardware centered on the aforementioned conditions.

Fidelity Growth Partners is a global venture capital firm dedicated to supporting ambitious entrepreneurs. With over 20 years of venture capital experience in China, it has invested in more than 85 companies across sectors including healthcare, enterprise IT, fintech, and consumer industries. As the proprietary investment arm of Fidelity International, Fidelity Growth Partners is committed to backing bold and impactful enterprises. Over the past decade, Fidelity Growth Partners and its affiliated funds have invested nearly $6 billion globally in growth-stage companies. In China’s healthcare sector, Fidelity Growth Partners boasts over 20 years of investment experience, focusing on early-stage medical investments and building a strategic layout across the entire industry chain. To date, its total investment in China’s healthcare sector exceeds $650 million.